

August 24, 2016

Brian Duda Senior Director, Strategic Pricing and Contracting Sunovion Pharmaceuticals, Inc. 84 Waterford Drive Malborough, MA 01752-7010

TO LEAVE WITHOUT EFFECT THE LETTER DATED AUGUST 1, 2016 REGARDING TERMINATION OF AGREEMENT FOR LATUDA

Dear Mr. Duda:

This letter is intended to leave without effect the Letter of Termination of Agreement sent to you on August 1st, 2016. We hereby inform you that all contracted presentations of LATUDA, listed on ADDENDUM A of the agreement, will continue in the Covered Drug Formulary (CDF) for Mental Health.

The Physical and Mental Health Rebate Agreement (effective January 1, 2015) at San Juan, Puerto Rico, by and between the *PUERTO RICO HEALTH INSURANCE ADMINISTRATION* and Sunovion Pharmaceuticals, Inc. will continue as established.

Sunovion Pharmaceuticals, Inc. must continue to honor and be responsible for paying the Rebates and Administrative Fees, as established in the terms of the Agreement. Abarca health will continue sending Sunovion Pharmaceuticals, Inc. Rebate Statements and Invoices as usual.

Cordially,

Ricardo A. Rivera Cardona

Executive Director

c: abarca health MC-21 Corporation

